Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib for Moderate to Severe Atopic Dermatitis in Indian Participants Aged 12 and Older
2024-000141-26Phase 3
- Sponsor
- Pfizer
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abrocitinib in atopic dermatitis (AD) (2 arms), sponsored by Pfizer. Primary endpoint: Incidence of adverse events and serious adverse events.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-000141-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000141-26.